AstraZeneca, along with its global biologics research and development arm, MedImmune, will showcase the growing potential of its broad portfolio of cancer medicines through 46 scientific presentations, at the European Society for Medical Oncology (ESMO) 2016 Congress in Copenhagen, Denmark, from 7-11 October 2016.
Highlights include new 1st-line data demonstrating superiority of Faslodex (fulvestrant) to a standard-of-care, aromatase inhibitor medicine, Arimidex (anastrazole), in postmenopausal women with HR+ locally-advanced or metastatic breast cancer who have not been previously treated with any hormonal medicine. The Company will also present updated safety and efficacy data from the Study 1108 durvalumab monotherapy cohort in non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC), in addition to a comparative analysis of PD-L1 diagnostic assays in 500 HNSCC tumour samples.
Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “Faslodex is an important treatment option for women with breast cancer. The FALCON trial illustrates how an approved medicine can further improve outcomes in patients with metastatic breast cancer. Additionally, our immuno-oncology presentations demonstrate our commitment to advancing innovation in lung and head and neck cancers, with pivotal data anticipated in the coming year.”
